These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36343306)

  • 1. In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations.
    Lannes R; Samur M; Perrot A; Mazzotti C; Divoux M; Cazaubiel T; Leleu X; Schavgoulidze A; Chretien ML; Manier S; Adiko D; Orsini-Piocelle F; Lifermann F; Brechignac S; Gastaud L; Bouscary D; Macro M; Cleynen A; Mohty M; Munshi N; Corre J; Avet-Loiseau H
    J Clin Oncol; 2023 Mar; 41(9):1695-1702. PubMed ID: 36343306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
    Cui J; Lv R; Yu T; Yan W; Xu J; Fan H; Li L; Liu Y; Du C; Deng S; Sui W; Xu Y; Yi S; Zou D; Qiu L; An G
    Haematologica; 2024 Feb; 109(2):591-603. PubMed ID: 37534514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma.
    Yang P; Chen H; Liang X; Xu W; Yu S; Huang W; Yi X; Guo Q; Tian M; Yue T; Li M; Zhang Y; Zhang M; Yan Y; Hu Z; Kumar SK; Zhou F; Dai Y; Jin F
    Am J Hematol; 2023 Feb; 98(2):251-263. PubMed ID: 36309982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
    Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
    Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
    Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
    Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
    Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
    Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real-world Swedish population receiving modern treatment.
    Lemonakis K; Olsson-Arvidsson L; Karlsson C; Johansson B; Hansson M
    Eur J Haematol; 2023 Sep; 111(3):391-399. PubMed ID: 37271732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial.
    Croft J; Ellis S; Sherborne AL; Sharp K; Price A; Jenner MW; Drayson MT; Owen RG; Chown S; Lindsay J; Karunanithi K; Hunter H; Gregory WM; Davies FE; Morgan GJ; Cook G; Atanesyan L; Savola S; Cairns DA; Jackson G; Houlston RS; Kaiser MF
    Leukemia; 2021 Jul; 35(7):2043-2053. PubMed ID: 33262523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization reveals the evolutionary biology of minor clone of gain/amp(1q) in multiple myeloma.
    Cui J; Liu Y; Lv R; Yan W; Xu J; Li L; Du C; Yu T; Zhang S; Deng S; Sui W; Hao M; Yi S; Zou D; Qiu L; Xu Y; An G
    Leukemia; 2024 Jun; 38(6):1299-1306. PubMed ID: 38609496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
    Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J; Goyal S; Chen Z; Boise LH; Lonial S; Nooka AK; Kaufman JL
    Blood Cancer J; 2019 Nov; 9(12):94. PubMed ID: 31767829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal fluorescence
    Merz M; Jauch A; Hielscher T; Mai EK; Seckinger A; Hose D; Bertsch U; Neben K; Raab MS; Salwender H; Blau IW; Lindemann HW; Schmidt-Wolf I; Scheid C; Haenel M; Weisel K; Goldschmidt H; Hillengass J
    Haematologica; 2017 Aug; 102(8):1432-1438. PubMed ID: 28495913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma.
    Salomon-Perzyński A; Bluszcz A; Krzywdzińska A; Spyra-Górny Z; Jakacka N; Barankiewicz J; Borg K; Solarska I; Szpila T; Puła B; Grosicki S; Jamroziak K
    Pol Arch Intern Med; 2020 Jun; 130(6):483-491. PubMed ID: 32338840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma.
    Locher M; Jukic E; Vogi V; Keller MA; Kröll T; Schwendinger S; Oberhuber K; Verdorfer I; Mühlegger BE; Witsch-Baumgartner M; Nachbaur D; Willenbacher W; Gunsilius E; Wolf D; Zschocke J; Steiner N
    Eur J Haematol; 2023 Mar; 110(3):296-304. PubMed ID: 36433728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
    D'Agostino M; Cairns DA; Lahuerta JJ; Wester R; Bertsch U; Waage A; Zamagni E; Mateos MV; Dall'Olio D; van de Donk NWCJ; Jackson G; Rocchi S; Salwender H; Bladé Creixenti J; van der Holt B; Castellani G; Bonello F; Capra A; Mai EK; Dürig J; Gay F; Zweegman S; Cavo M; Kaiser MF; Goldschmidt H; Hernández Rivas JM; Larocca A; Cook G; San-Miguel JF; Boccadoro M; Sonneveld P
    J Clin Oncol; 2022 Oct; 40(29):3406-3418. PubMed ID: 35605179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China.
    Chen Q; Han X; Zheng G; Yang Y; Li Y; Zhang E; Yang L; Dong M; He D; He J; Cai Z
    Front Oncol; 2022; 12():1084683. PubMed ID: 36605445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.